A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
What is the purpose of this trial?
This is a pilot study of patients who previously received platinum chemotherapy with recurrent SCLC to evaluate the change in the ratio of intratumoral Teff/Treg cells and clinical benefit of treatment with nivolumab and ipilumumab.
- Trial withYale Cancer Center
- Start Date12/05/2018
- End Date06/07/2020
- Last Updated12/07/2018
- Study HIC#2000023361